カナダ - 英語 - Health Canada

glaxosmithkline inc - fluticasone propionate - metered-dose aerosol - 125mcg - fluticasone propionate 125mcg - adrenals

カナダ - 英語 - Health Canada

glaxosmithkline inc - salmeterol (salmeterol xinafoate); fluticasone propionate - aerosol, metered dose - 25mcg; 125mcg - salmeterol (salmeterol xinafoate) 25mcg; fluticasone propionate 125mcg - selective beta 2-adrenergic agonists

カナダ - 英語 - Health Canada

teva canada limited - fluticasone propionate - metered-dose pump - 50mcg - fluticasone propionate 50mcg - corticosteroids

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

glaxosmithkline llc - fluticasone furoate (unii: js86977wnv) (fluticasone - unii:cut2w21n7u) - fluticasone furoate 27.5 ug - veramyst® (fluticasone furoate) nasal spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older. veramyst nasal spray is contraindicated in patients with hypersensitivity to any of its ingredients [see warnings and precautions (5.3)] . teratogenic effects pregnancy category c. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. there were no teratogenic effects in rats and rabbits at inhaled fluticasone furoate dosages of up to 91 and 8 mcg/kg/day, respectively (approximately 7 and 1 times, respectively, the maximum recommended daily intranasal dose in adults on a mcg/m2 basis). there was also no effect on pre- or post-natal development in rats treated with up to 27 mcg/kg/day by inhalation during gestation and lactation (approximately 2 times the maximum recommended daily intranasal dose in adults on a mcg/m2 basis). there are no adequate and well-co

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspire pharma ltd - fluticasone propionate - cutaneous cream - 500microgram/1gram

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - fluticasone propionate - cutaneous cream - 500microgram/1gram

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25mcg /125 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals sa-nv - salmeterol xinafoate 36,3 µg/dose - eq. salmeterol 25 µg/dose; fluticasone propionate 125 µg/dose - pressurised inhalation, suspension - 25 µg/dose - 125 µg/dose - fluticasone propionate 125 µg/dose; salmeterol xinafoate 36.3 µg/dose - salmeterol and fluticasone

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - fluticasone propionate - cutaneous cream - 500microgram/1gram

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and in children ages 1 year and older.